A Rational Designed Novel Bispecific Antibody for the Treatment of GBM

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM

Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for GBM. Recently, bispecific antibodies (BsAbs) have shown exciting clinical benefits in cancer immunotherapy. Here,...

Full description

Bibliographic Details
Main Authors: Rui Sun, Yuexian Zhou, Lei Han, Zhidi Pan, Jie Chen, Huifang Zong, Yanlin Bian, Hua Jiang, Baohong Zhang, Jianwei Zhu
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Biomedicines
Subjects:
bispecific antibody
GBM
EGFRvIII
split intein
Online Access:https://www.mdpi.com/2227-9059/9/6/640

Internet

https://www.mdpi.com/2227-9059/9/6/640

Similar Items